Modeled onset geometry for sildenafil 100 mg is a PK→PD construct describing how absorption rate, absorption timing, solubility, gastric emptying, distribution loading, distribution geometry, clearance geometry, and dose-scaling geometry shape the rising phase. “Onset” here refers strictly to modeled PK→PD behavior, not real-world timing. Absorption rate controls rising-phase steepness, absorption timing controls temporal alignment, solubility represents dissolution-driven availability, and gastric emptying controls modeled input arrival. Distribution loading represents early central availability, while distribution geometry describes compartmental spread and redistribution. Clearance geometry describes removal across the modeled concentration trajectory, and dose-scaling geometry represents how a 100 mg input differs parametrically from lower-dose trajectories. PD interpretation then maps this PK curve into onset geometry: threshold placement defines the modeled boundary, binding sensitivity transforms concentration differences, coupling geometry shapes downstream transitions, and PD noise bands add an interpretation region. Link to onset time.
Modeled peak and Tmax geometry for sildenafil 100 mg describes the shape and coordinates of the concentration trajectory rather than a real-world timing claim. Faster modeled absorption steepens the rising phase, earlier absorption timing shifts that phase leftward, solubility represents dissolution-driven availability, and gastric-emptying variability shifts modeled input arrival. Distribution loading determines early central-compartment concentration, while distribution geometry determines how absorbed material spreads across compartments. Redistribution timing can alter peak curvature by changing when material moves between compartments, while clearance geometry controls removal during and after the rising phase. Dose-scaling geometry determines how peak amplitude and curvature are represented relative to 25 mg and 50 mg trajectories. Concentration-dependent clearance can further modify trajectory curvature when the model includes concentration-linked removal. In peak and Tmax modeling, these PK features supply the input curve that PD parameters transform into modeled coordinates. Link to peak sildenafil.
Modeled “effectiveness geometry” for sildenafil 100 mg describes how a PD function interprets modeled PK concentration differences, not real-world effectiveness or outcomes. Threshold placement determines where the modeled concentration curve intersects a PD boundary. Binding sensitivity determines how concentration differences are transformed into binding differences; greater modeled sensitivity can expand separation, while lower sensitivity can compress it. Coupling geometry determines how binding is mapped into downstream PD signals; shallow slopes broaden transitions, while steep slopes compress them. PD noise bands widen or narrow the modeled interpretation region around those transitions. A 100 mg trajectory can be represented by different parameter sets for absorption rate, solubility, gastric emptying, distribution loading, redistribution timing, and Tmax/Cmax geometry. PD mapping can therefore expand, compress, shift, or reshape modeled effectiveness geometry even when the dose label remains fixed in the model. Link to speed vs effectiveness.
For 100 mg speed modeling, the PK trajectory is generated by the interaction of input, distribution, and removal parameters rather than by dose alone. Absorption rate controls the modeled steepness of concentration increase, absorption timing positions the input along the time axis, solubility shapes dissolution-driven availability, and gastric emptying shifts when modeled material enters the absorption process. Absorption-window width controls whether input is concentrated or distributed across time. Distribution loading establishes early central availability, while distribution geometry and redistribution timing determine compartmental movement and peak curvature. First-pass metabolism and bioavailability scale the amount reaching the modeled systemic circulation. Clearance geometry and concentration-dependent clearance then shape the descending and curvature components of the trajectory. Dose-scaling geometry represents how these relationships are parameterized at 100 mg relative to other modeled doses. Together, these PK features define the concentration curve subsequently interpreted by PD functions. Link to absorption rate.
PK variability produces different modeled onset, peak, and effectiveness regions for sildenafil 100 mg because each parameter set can alter a different geometric feature of the concentration trajectory. A faster absorption rate can steepen the rising phase, while slower absorption can broaden it. Changes in absorption timing or gastric emptying shift input alignment; solubility changes the modeled availability profile; and absorption-window width changes how concentrated the input is over time. Distribution loading, distribution geometry, and redistribution timing modify central-compartment loading and peak curvature. First-pass metabolism and bioavailability alter systemic input magnitude, while clearance geometry and concentration-dependent clearance reshape persistence and the descending phase. These differences can change modeled Tmax and Cmax coordinates without implying a fixed real-world interval. When the resulting PK trajectories are passed through threshold, binding, coupling, and noise functions, the same PK variation can generate distinct modeled onset-speed, peak-speed, and effectiveness-geometry regions. Link to distribution speed.
| PK Domain | 100 mg Interaction | Link |
|---|---|---|
| Absorption Rate | Steeper or flatter rising phase. | absorption rate |
| Distribution Geometry | Compartmental spread. | distribution speed |
| Clearance | Removal geometry. | elimination speed |
Threshold placement determines how a sildenafil 100 mg PK trajectory is converted into modeled onset, peak, and effectiveness coordinates. A threshold is a mathematical boundary within the PD model, not a clinical timing rule. If the threshold is positioned lower relative to a given concentration trajectory, the modeled crossing occurs at a different coordinate than when the threshold is positioned higher. The same PK curve can therefore generate different onset-geometry coordinates under different threshold placements. Binding sensitivity then determines how concentration changes are translated into modeled binding changes around that boundary. Coupling geometry maps binding into a downstream PD signal, allowing the model to represent shallow, intermediate, or steep transitions. PD noise bands represent a modeled region around the nominal signal, widening or narrowing the apparent coordinate range without creating a real-world timing claim. These PD parameters transform the same 100 mg PK trajectory into alternative modeled speed geometries. Link to pd speed.
Binding sensitivity, coupling geometry, and PD noise bands determine how strongly PK differences are expressed after a sildenafil 100 mg concentration trajectory enters the PD model. Binding sensitivity controls the local conversion from concentration differences to modeled binding differences. A steeper sensitivity function can increase geometric separation between trajectories, whereas a flatter function can compress separation. Coupling geometry then determines how binding differences propagate into the modeled downstream signal, with slope and curvature controlling transition shape. PD noise bands add a bounded interpretation region around the modeled signal, so small PK differences may remain visually separated, overlap, or become less distinguishable depending on the specified band. PK speed itself remains a separate input geometry: absorption rate, distribution loading, clearance geometry, Tmax, and Cmax determine the concentration trajectory before PD transformation. Thus, the combined model can represent amplification, compression, overlap, or curvature changes without translating them into real-world outcomes. Link to pk speed.
| PD Domain | 100 mg Effect | Link |
|---|---|---|
| Threshold Placement | Earlier/later onset/peak coordinate. | onset time |
| Binding Sensitivity | Amplification/compression. | onset variability comparison |
| Coupling Geometry | Slope-driven shaping. | peak variability comparison |
Modeled 100 mg onset, peak, and effectiveness differences are determined by the parameter configuration used to generate and interpret the PK concentration trajectory. Absorption rate, absorption timing, gastric emptying, solubility, and absorption-window width shape modeled input. Distribution loading, distribution geometry, and redistribution timing shape how that input is represented. First-pass metabolism and bioavailability influence modeled systemic input, while clearance geometry and concentration-dependent clearance shape removal and curvature. Dose-scaling geometry specifies how the 100 mg trajectory is parameterized relative to other modeled doses. The resulting PK curve is then passed through PD functions. Threshold placement determines boundary crossings, binding sensitivity controls concentration-to-binding transformation, coupling geometry determines downstream signal shape, and PD noise bands define an interpretation region. Therefore, “onset,” “peak,” “speed,” and “effectiveness” describe model coordinates, not real-world timing or outcomes.
The main PK mechanisms are absorption, distribution, metabolism, and elimination geometry. Absorption rate determines modeled rising-phase steepness, while absorption timing positions input along the time axis. Gastric emptying influences when modeled material reaches the absorption process, and solubility influences dissolution-driven availability. Absorption-window width determines whether input is concentrated or spread across time. Distribution loading controls early central availability, distribution geometry describes compartmental spread, and redistribution timing influences movement between compartments. First-pass metabolism and bioavailability determine how much modeled input reaches systemic circulation. Clearance geometry and concentration-dependent clearance determine removal and trajectory curvature. Dose-scaling geometry represents the parameterized relationship between the 100 mg trajectory and lower-dose trajectories. These mechanisms generate the PK curve that supplies the input for modeled onset, peak, and PK→PD effectiveness geometry.
The principal PD mechanisms are threshold placement, binding sensitivity, coupling geometry, and PD noise bands. Threshold placement defines the modeled boundary against which the PK concentration trajectory is evaluated, so changing its position changes the calculated crossing coordinate. Binding sensitivity determines how strongly a concentration difference is converted into a modeled binding difference. Coupling geometry then maps binding into a downstream PD signal, with slope and curvature controlling the shape of that transformation. PD noise bands represent a specified interpretation region around the nominal signal and can change how closely neighboring modeled trajectories appear. These parameters operate after the PK trajectory has been generated, so they do not replace absorption, distribution, or clearance geometry. Instead, they transform PK differences into modeled onset-speed, peak-speed, and effectiveness-geometry differences. In this framework, “effectiveness” is strictly a mathematical PK→PD construct and does not represent real-world effectiveness, outcomes, or a clinical timing interval.
Modeled 100 mg trajectories differ across parameter sets because the dose value does not uniquely specify the geometry of absorption, distribution, metabolism, elimination, or PD transformation. One parameter set may use a steeper absorption rate, earlier absorption timing, narrower absorption-window width, or different gastric-emptying representation. Another may use different solubility, distribution loading, compartmental geometry, redistribution timing, first-pass metabolism, bioavailability, or clearance assumptions. These choices change the shape, position, amplitude, and curvature of the modeled concentration trajectory, including Tmax and Cmax geometry. The PD layer can further separate or compress trajectories through threshold placement, binding sensitivity, coupling geometry, and noise bands. Dose-scaling geometry then describes how the 100 mg parameterization relates to other modeled doses. Consequently, different parameter sets can produce different modeled onset, peak, and effectiveness geometries even when every trajectory is labeled 100 mg. The differences are model outputs, not real-world timing or outcome claims.
PK→PD mapping explains 100 mg differences by separating concentration generation from signal interpretation. The PK layer first generates a modeled trajectory from absorption rate, absorption timing, gastric emptying, solubility, absorption-window width, distribution loading, distribution geometry, redistribution timing, first-pass metabolism, bioavailability, and clearance geometry. Dose-scaling geometry specifies how the 100 mg trajectory is represented relative to other modeled doses, while Tmax and Cmax describe features of that trajectory. The PD layer then applies threshold placement, binding sensitivity, coupling geometry, and noise bands. A threshold converts concentration into a modeled boundary-crossing coordinate; binding sensitivity converts concentration differences into binding differences; coupling geometry transforms those differences into a downstream signal; and noise bands define an interpretation region. The resulting onset-speed, peak-speed, and effectiveness geometry therefore depends on both PK and PD parameterization. “Effectiveness” remains a modeled PK→PD construct, with no implication of real-world effectiveness, outcomes, or timing.